Alvotech (NASDAQ:ALVO) Given Average Recommendation of "Hold" by Analysts

Key Points

• Analysts maintain a “Hold” consensus on Alvotech, with two sell, two hold and three buy ratings. The average 12-month price target is $7.60, versus a recent share price of $4.43.
• Alvotech’s quarterly loss of $0.11 per share was wider than the expected $0.05 loss, although revenue of $105.77 million exceeded estimates. The company remains unprofitable, with a negative net margin of 36.31%.
• Potential catalysts include FDA decisions on three biosimilar applications expected in the fourth quarter of 2026 and a licensing deal valued at up to approximately $150 million. However, first-half revenue and adjusted EBITDA declined sharply, while recent equity financing could dilute shareholders.

Alvotech (NASDAQ:ALVO - Get Free Report) has been given a consensus recommendation of "Hold" by the seven analysts that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12-month target price among analysts that have covered the stock in the last year is $7.60.

ALVO has been the topic of a number of research analyst reports. Evercore assumed coverage on shares of Alvotech in a report on Friday, August 14th. They set an "outperform" rating on the stock. Weiss Ratings downgraded Alvotech from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, June 9th. Finally, Wall Street Zen lowered Alvotech from a "hold" rating to a "sell" rating in a report on Saturday, May 23rd.

Alvotech Stock Performance

Alvotech stock opened at $4.43 on Monday. The stock has a market cap of $1.34 billion, a PE ratio of -7.26 and a beta of 0.18. The stock has a 50-day moving average of $3.66 and a two-hundred day moving average of $3.73. Alvotech has a one year low of $2.94 and a one year high of $9.25.

Alvotech (NASDAQ:ALVO - Get Free Report) last posted its quarterly earnings data on Wednesday, August 19th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.06). The company had revenue of $105.77 million for the quarter, compared to analyst estimates of $103.00 million. Alvotech had a negative net margin of 36.31% and a negative return on equity of 11.92%. As a group, sell-side analysts predict that Alvotech will post 0.05 EPS for the current fiscal year.

Institutional Investors Weigh In On Alvotech

A number of large investors have recently bought and sold shares of ALVO. Jane Street Group LLC purchased a new position in Alvotech during the 4th quarter worth approximately $474,000. Citadel Advisors LLC purchased a new stake in shares of Alvotech in the 3rd quarter valued at $346,000. Amundi increased its stake in shares of Alvotech by 71.0% in the third quarter. Amundi now owns 19,416 shares of the company's stock worth $167,000 after acquiring an additional 8,059 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Alvotech by 30.4% in the third quarter. JPMorgan Chase & Co. now owns 24,455 shares of the company's stock worth $200,000 after acquiring an additional 5,697 shares during the period. Finally, Bank of America Corp DE raised its holdings in shares of Alvotech by 218.0% during the second quarter. Bank of America Corp DE now owns 16,623 shares of the company's stock worth $152,000 after purchasing an additional 11,395 shares during the last quarter.

Alvotech News Roundup

Here are the key news stories impacting Alvotech this week:

• Positive Sentiment: Alvotech signed a licensing and commercialization agreement with Lotus Pharmaceutical covering proposed biosimilars AVT34, targeting Imfinzi (durvalumab), and AVT87, targeting Hemlibra (emicizumab), in the United States and selected Asian markets. The deal is valued at up to approximately $150 million and expands Alvotech’s potential commercial reach. Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical
• Positive Sentiment: The FDA accepted resubmitted applications for AVT05, a proposed Simponi biosimilar, AVT06, a proposed Eylea biosimilar, and partner Dr. Reddy’s AVT03, targeting Prolia/Xgeva. FDA decisions are expected in the fourth quarter of 2026, creating important approval and launch catalysts. Alvotech Announces Financial Results for the First Half of 2026
• Positive Sentiment: Alvotech said manufacturing returned to planned operating levels near the end of the second quarter after facility improvements constrained output. Management expects stronger product availability and commercial performance in the second half, supported by strong underlying demand in the U.S. and Europe.
• Positive Sentiment: The company projects 2026 revenue of $650 million to $700 million and adjusted EBITDA of $180 million to $220 million. It also strengthened liquidity with approximately $165 million from an equity offering and private placement, plus a new $75 million term loan.
• Neutral Sentiment: Alvotech’s Reykjavik facility received a “Voluntary Action Indicated” classification following an FDA inspection, a favorable compliance outcome but not a product approval.
• Negative Sentiment: First-half adjusted revenue fell 30.8% to $211.9 million, while product and service revenue dropped 48.3%. Adjusted EBITDA declined to $46.9 million, and cash decreased to $142.8 million, highlighting execution and liquidity concerns.
• Negative Sentiment: Second-quarter adjusted loss was $0.11 per share, wider than the expected $0.05 loss, although quarterly revenue of $105.77 million exceeded estimates. The equity financing also creates potential shareholder dilution.

Alvotech Company Profile

Alvotech NASDAQ: ALVO is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high‐quality, cost‐effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in‐house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers.

Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source